Abstract:This formulated PDMN constitutes a biological product that preferentially colonizes and penetrates into tumor regions, as well as activates STING on dendritic cells, leading to the differentiation of cell‐mediated immunity and secretion of proinflammatory cytokines. This STING‐amplified biotherapy efficiently restrains the growth of local and distant tumors, and shows synergy when combined with PD‐1 blockade to elicit a long‐lived immunity. Stimulator of interferon genes (STING) connects the innate immunity to potent adaptive immunity via multiple pathways, which play a critical role in cancer treatment. Clinical application of STING agonists is mainly restrained due to the metabolic instability caused by intrinsic cyclic dinucleotide ligands. Previously, an orally available non‐nucleotide human STING agonist, MSA‐2 is presented, and to further improve its therapeutic efficacy, this work leverages the nonpathogenic Escherichia coli Nissle 1917 for tumor‐targeted delivery of the STING agonist by coating biocompatible polydopamine on the bacterial surface, termed as PDMN. The engineered bacterial delivery platform holds potential in elevating levels of type I interferon (IFN) along with proinflammatory cytokines and inducing maturation on dendritic cells. Intravenous administration of PDMN with laser irradiation to the tumor region promotes IFN‐β expression in a tumor microenvironment and mounts both the innate and adaptive immune responses, leading to profound regressions of established melanoma and hepatocellular carcinoma in mice. By synergized with anti‐PD‐1 therapy, a substantial long‐lived protective immunity is generated, capable of preventing distant tumor metastases. Hence, this study identifies a STING‐amplified biotherapy to shape the cell‐mediated antitumor immunity, serving as a potential personalized cancer vaccine with enhanced biosafety and immune activation profile for diverse applications.

Engineering Metal-Based Hydrogel Mediated Tertiary Lymphoid Structure Formation via Activating STING Pathway for Enhanced Immunotherapy

Immunotherapeutic Hydrogel with Photothermal Induced Immunogenic Cell Death and STING Activation for Post‐Surgical Treatment

Cell-to-cell communications of cGAS-STING pathway in tumor immune microenvironment.

STINGing the tumor microenvironment to promote therapeutic tertiary lymphoid organogenesis

Environmentally responsive hydrogel promotes vascular normalization to enhance STING anti-tumor immunity

Self-Oxygenated Hydrogel Enhances Immune Cell Response and Infiltration Via Triggering Dual DNA Damage to Activate cGAS-STING and Inhibiting CAFs

Enhancing immunotherapy outcomes by targeted remodeling of the tumor microenvironment via combined cGAS-STING pathway strategies

STINGing the Tumor Microenvironment to Promote Therapeutic Tertiary Lymphoid Structure Development

An engineered hydrogel with low-dose antitumor drugs enhances tumor immunotherapy through tumor interstitial wrap

Dual-pathway STING activation and chemodynamic therapy for improved anti-tumor therapy

Enhanced Tumor Immunotherapy by Triple Amplification Effects of Nanomedicine on the STING Signaling Pathway in Dendritic Cells

Spatiotemporal release of non-nucleotide STING agonist and AKT inhibitor from implantable 3D-printed scaffold for amplified cancer immunotherapy

Activation of the cGAS-STING pathway combined with CRISPR-Cas9 gene editing triggering long-term immunotherapy

Potentiating the Systemic Immunity by Bacteria‐Delivered Sting Activation in a Tumor Microenvironment

Tumor Microenvironment‐Responsive Nanoparticles Amplifying STING Signaling Pathway for Cancer Immunotherapy

Triple-pathway cGAS-STING activation collaborated with ferroptosis-induced immunogenic cell death for boosting systemic colorectal cancer immunotherapy

Multifunctional hybrid exosomes enhanced cancer chemo-immunotherapy by activating the STING pathway

Robust and Sustained STING Pathway Activation via Hydrogel-Based In Situ Vaccination for Cancer Immunotherapy

Metal-Cyclic Dinucleotide Nanomodulator-Stimulated STING Signaling for Strengthened Radioimmunotherapy of Large Tumor

Activation of Stimulation of Interferon Genes (STING) Signal and Cancer Immunotherapy

Tumor-responsive Covalent Organic Polymeric Nanoparticles Enhancing STING Activation for Cancer Immunotherapy